This increase appears to be a beneficial response, as treatment with exogenous erythropoietin or its analogues has been shown to be beneficial in multiple preclinical models of sepsis through its pleiotropic protective effects, including its ability to modulate the immune response [60,61,62,63,64,65]. This evidence concerns the gene EPO and Sepsis.